Nkarta Initiates Ntrust-1 Of NKX019 In Lupus Nephritis, With First Patient In Screening. FDA Also Clears Second Investigational New Drug Application For NKX019 In Autoimmune Disease
Portfolio Pulse from Benzinga Newsdesk
Nkarta has initiated the Ntrust-1 study of NKX019 in lupus nephritis, with the first patient in screening. Additionally, the FDA has cleared a second investigational new drug application for NKX019 in autoimmune disease.
June 27, 2024 | 10:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nkarta has started the Ntrust-1 study of NKX019 in lupus nephritis and received FDA clearance for a second IND for NKX019 in autoimmune disease.
The initiation of the Ntrust-1 study and FDA clearance for a second IND are positive developments for Nkarta. These milestones could lead to advancements in their product pipeline, potentially boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100